Ticker Hub
AKTS — AI Analysis & Sentiment
3 recent AI-generated analyses for AKTS. Sentiment and confidence insights updated continuously.
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
Aktis Oncology has released promising early clinical data for its AKY-2519 cancer drug, suggesting a strong safety and efficacy profile. This posit...
May 21, 2026Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Aktis Oncology's Q1 update highlights key clinical advancements, including a Fast Track designation and new trial initiations, alongside a robust c...
May 11, 2026Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
FDA Fast Track designation for AKY-1189 is a key regulatory achievement for Aktis Oncology, expediting the development of a critical therapy for an...
Feb 24, 2026